Website: twistbioscience.com   |   LinkedIn: linkedin.com/company/twist-bioscience

Writing DNA at Scale

How Twist Bioscience turned silicon-based DNA synthesis into the engine behind modern genomics, drug discovery, and AI-driven biology

At a glance

  • Company: Twist Bioscience (twistbioscience.com), NASDAQ: TWST
  • Headquarters: South San Francisco, California
  • Focus: Synthetic DNA and DNA-based products: genes, oligo pools, NGS target enrichment, and protein and antibody discovery solutions
  • Fiscal 2026: record revenue of $459.4 million, up 22% year over year
  • Working with PSG on: Fractional business development

A new way to make DNA

For decades, synthetic DNA was made one tube at a time. Twist changed the math. Its proprietary platform writes DNA on silicon, miniaturizing the chemistry so thousands of sequences can be made in parallel, with high quality and at a scale traditional methods can’t match.

That single breakthrough has grown into a broad portfolio serving researchers in academia, diagnostics, and biopharma around the world.

What Twist delivers

  • DNA synthesis: genes, gene fragments, clonal genes, and oligo pools for synthetic biology, cloning, and library construction
  • NGS applications: target enrichment panels and workflows that power genomic research and clinical diagnostics
  • Protein and antibody solutions: discovery, optimization, and characterization services for biopharma
  • Fuel for AI-enabled discovery: high-throughput DNA that lets AI-driven drug discovery teams design, build, and test at scale

Momentum you can measure

Twist just closed a record fiscal 2026. Revenue reached $459.4 million, up 22%, with Q4 marking its 15th consecutive quarter of sequential growth and gross margin improving to 52.4%. Growth has been led by DNA Synthesis and Protein Solutions, where customers pursuing AI-enabled discovery are scaling up, and by strong uptake from pharma and biotech therapeutics teams.